IntarciaGetting closer in the quest to create a less-intrusive way to take medicine, Intarcia is looking beneath the surface –  that is, beneath your surface. The company’s ITCA 650 is a matchstick-sized device (at left) implanted under the skin that delivers a continuous dose of the type 2 medication exenatide. But while exenatide is traditionally delivered via twice-a-day or once-weekly injections, the ICTA 650 would need to be implanted only once a year. The device is currently in it’s final Phase 3 trials in humans, to test for any cardiovascular  risks, and the company plans to file for FDA clearance early next year.